Conference
A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study
Authors
Foster GR; Thompson AJ; Ruane PJ; Borgia SM; Dore G; Workowski K; Hyland RH; Wang J; Svarovskaia ES; Stamm LM
Volume
64
Pagination
pp. 135A-136A
Publisher
WILEY
Publication Date
10 2016
Name of conference
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Conference place
MA, Boston
Conference start date
November 11, 2016
Conference end date
November 15, 2016
Conference proceedings
HEPATOLOGY
ISSN
0270-9139